Lys248
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys248  -  HMGCR (mouse)

Site Information
VLEEEENkPNPVTQR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 10844794

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 1 )
Disease tissue studied:
leukemia ( 9 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 4 , 5 , 6 , 7 , 8 ) , ES-J1 (stem) ( 3 ) , liver ( 1 , 2 ) , pooled tissues ( 2 ) , RAW 264.7 (macrophage) ( 9 )

Downstream Regulation
Effects of modification on HMGCR:
protein degradation ( 1 )

References 

1

Hwang S, et al. (2016) Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver. J Biol Chem 291, 13479-94
27129778   Curated Info

2

Wagner SA, et al. (2012) Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 11, 1578-85
22790023   Curated Info

3

Zhou J (2010) CST Curation Set: 9129; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

4

Tucker M (2010) CST Curation Set: 9088; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

5

Tucker M (2010) CST Curation Set: 9085; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

6

Tucker M (2010) CST Curation Set: 9087; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

7

Tucker M (2010) CST Curation Set: 9086; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

8

Tucker M (2010) CST Curation Set: 9083; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

9

Possemato A (2009) CST Curation Set: 6916; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/untreated; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info